stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Revenue growth
PTC Therapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was −35.1%, down 149.6 percentage points from fiscal 2025 (114.5%). Over the past ten years it has ranged from −14.0% (fiscal 2024) to 135.0% (fiscal 2017); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 114.5% | 128.48 |
| FY2024 | −14.0% | (48.17) |
| FY2023 | 34.2% | 4.45 |
| FY2022 | 29.8% | (11.70) |
| FY2021 | 41.5% | 17.41 |
| FY2020 | 24.0% | 8.08 |
| FY2019 | 16.0% | (20.23) |
| FY2018 | 36.2% | (98.85) |
| FY2017 | 135.0% | 10.09 |
| FY2016 | 125.0% | 79.31 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 69.6% | (31.98) |
| Jun 2026 | 101.6% | 178.38 |
| Mar 2026 | −76.8% | (54.08) |
| Dec 2025 | −22.8% | (29.98) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CGON CG Oncology, Inc. compare | 840.8% |
| SRRK Scholar Rock Holding Corporation compare | 213.7% |
| COGT Cogent Biosciences, Inc. compare | 110.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 42.2% |
| PTCT PTC Therapeutics, Inc. | −35.1% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement